Dehydroepiandrosterone replacement therapy

European Journal of Endocrinology

Volumn 145, Issue 2, 2001, Pages 103-106

  Gurnell, E M ^a   Chatterjee, V K K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRASTERONE;

ADRENAL CORTEX; ADRENAL INSUFFICIENCY; ADULT; AGED; AGING; CIRCULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MALE; PRIORITY JOURNAL; REVIEW;

EID: 0034899706     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1450103     Document Type: Review

References (40)

1. Premature adrenarche - Normal variant or forerunner of adult disease?
2. Dehydroepiandrosterone sulfate and aging
3. Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect
4. Protection from glucocorticoid induced thymic involution by dehydroepiandrosterone
5. Dehydroepiandrosterone (DHEA) antagonises the neurotoxic effects of corticosterone and translocation of SAPK3 in hippocampal primary cultures
6. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood
7. Sexual dimorphism in the influence of advanced aging on adrenal hormone levels: The Rancho Bernardo Study
8. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease
9. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study
10. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer
11. Dehydroepiandrosterone sulphate and bone mineral density
12. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study
13. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: The Rancho Bernardo Study
14. A prospective study on cortisol, dehydroepiandrosterone sulfate and cognitive function in the elderly
15. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia
16. Plasma dehydroepiandrosterone sulfate in Alzheimer's disease
17. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus
18. Biotransformation of oral dehydroepiandrosterone in elderly men: Significant increase in circulating estrogens
19. Dehydroepiandrosterone replacement administration: Pharmacokinetic and pharmacodynamic studies in healthy elderly subjects
20. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age
21. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women
22. Dehydroepiandrosterone replacement in aging humans
23. Dehydroepiandrosterone (DHEA). DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue
24. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women
25. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women
26. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life
27. Quality of life in patients with Addison's disease: Effects of different cortisol replacement modes
28. Assessing the potential for finetuning the management of Addison's disease/steroid replacement therapy
29. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans
30. Oral dehydroepiandrosterone for adrenal androgen replacement: Pharmacokinetics and peripheral conversion to androgens and estrogens in young females after dexamethasone suppression
31. Dehydroepiandrosterone replacement in women with adrenal insufficiency
32. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease
33. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial
34. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease
35. Evaluation of glucocorticoid replacement therapy and of their effects on bone mineral density in Addison's disease
36. Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I
37. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women
38. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects
39. Wishing a dream came true: DHEA as a rejuvenating treatment?
40. Double-blind treatment of major depression with dehydroepiandrosterone